DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Dexcom Inc. director Mark G. Foletta reported indirect stock sales executed by The Foletta Family Trust under a pre-arranged Rule 10b5-1 trading plan. On June 15, 2026, the trust sold a total of 4,000 Dexcom common shares in open-market transactions at weighted average prices around $74 per share.
The filing shows two sale blocks: 3,801 shares at a weighted average price of $74.0991 and 199 shares at a weighted average price of $74.8187. Following the transactions, Foletta also reports holding 6,331 Dexcom shares directly.
Michael Brown submitted a Form 144 notice regarding a proposed sale of 1,700 shares of Common Stock. The filing lists the securities as Restricted Stock with an effective date of 03/08/2026 and shows Morgan Stanley Smith Barney LLC as the broker. The filing also records three recent sales of 1,700 shares each on 05/15/2026, 04/15/2026 and 03/16/2026 with transaction amounts of $101,847.00, $107,168.00 and $110,245.00, respectively.
Dexcom Inc. executive Jon Coleman reported open-market sales of company stock under a pre-arranged trading plan. On June 3, 2026, he sold 4,912 shares of common stock at $73.00 per share. On June 4, 2026, he sold an additional 4,911 shares at $74.13 per share.
These transactions, totaling 9,823 shares, were executed pursuant to a Rule 10b5-1 Plan adopted on March 4, 2026, which is designed to allow orderly, pre-scheduled dispositions. After these sales, Coleman directly held 95,450 shares of Dexcom common stock. A related disclosure notes that this number includes 95,450 unvested restricted stock units, consisting of 43,897 units granted March 8, 2026 vesting through March 8, 2029, and 51,553 units granted May 22, 2025 vesting through May 22, 2029. The filing shows no derivative positions remaining.
DXCM notice of proposed sale under Form 144: an affiliate lists 4911 shares of Common Stock as restricted stock to be sold 05/22/2026. The filing also records a sale of 4912 shares of Common Stock by Jon C. Coleman on 06/03/2026.
ALTMAN STEVEN R reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Steven R. Altman received a grant of 5,565 restricted stock units of DexCom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or DexCom's 2027 Annual Meeting of Stockholders. Each unit represents a contingent right to receive one share of common stock upon settlement. Following the grant, Altman holds 5,565 shares directly from this award and 63,667 shares indirectly through the Altman Family Trust, where he serves as trustee.
Malady Kyle reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Kyle Malady received an equity award in the form of restricted stock units. The Form 4 reports a grant of 5,575 shares of Common Stock at no cash cost as a compensation-related award, bringing his direct holdings to 28,242 shares.
The award is structured as RSUs, each representing a contingent right to receive one DexCom share upon settlement. According to the terms, 100% of the RSU award will vest on the earlier of one year after the May 28, 2026 grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders.
AUGUSTINOS NICHOLAS reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Nicholas Augustinos reported a new equity award and updated holdings. He received a grant of 5,575 restricted stock units (RSUs) on May 28, 2026, with each RSU representing one share of Dexcom common stock upon settlement.
The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Following this award, he holds 5,575 shares directly and 38,457 shares indirectly through the Kirschner/Augustinos Revocable Trust, where he serves as a trustee.
FOLETTA MARK G reported acquisition or exercise transactions in this Form 4 filing.
Dexcom director Mark G. Foletta received a grant of 6,331 restricted stock units (RSUs) of Dexcom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Each RSU represents a contingent right to receive one share of common stock upon settlement. After the grant, Foletta holds 6,331 shares directly and 56,852 shares indirectly through The Foletta Family Trust DTD 1/30/2015, where he serves as trustee.